News AZ's Tagrisso gets full US approval in lung cancer Phase 3 data confirmed its efficacy in patients with a certain mutation.
News Windward Bio catches $175m from its IPO Swiss biotech Windward Bio has raised $175m in its Nasdaq IPO as it prepares to take on some heavyweight rivals with its long-acting TSLP inhibitor.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.
